ArticleJournal of enzyme inhibition and medicinal chemistry2023
New pyrazolyl-thiazolidinone/thiazole derivatives as celecoxib/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory/anti-proliferative activities, apoptosis, molecular modelling and ADME studies.
Article in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Whole-volume histogram analysis of spectral-computed tomography iodine maps characterizes HER2 expression in gastric cancer.World journal of gastroenterology · 2024Trial
- Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Recent advances in thiazole-based derivatives targeting diverse anti-inflammatory pathways.RSC advances · 2026Review
- Design, synthesis, and anti-prostate cancer activity evaluation of novel thieno[2,3-b]pyridine derivatives as potential BLM helicase inhibitors.Molecular diversity · 2026Article
- Article
- A Review of Recent Advances in the Anticancer Mechanisms of Activity of Novel Thiazoles and 4-Thiazolidinones/Thiazolidinediones (2021-2025).Molecules (Basel, Switzerland) · 2026Review
- Article
- Discovery of novel purine analogues against breast cancer selectively targeting CDK2: optimization, synthesis, biological evaluation and docking study.Molecular diversity · 2026Article
- Novel pyrazole carboxylate derivatives as lonazolac bioisosteres with selective COX-2 inhibition: design, synthesis and anti-inflammatory activity.Molecular diversity · 2026Article
- In silico and In vitro studies of EGFR kinase and Anilide derivatives as inhibitors against Breast Cancer.Biotechnology notes (Amsterdam, Netherlands) · 2026Article
- Pyrazole Derivatives as Selective COX-2 Inhibitors: An Updated Review.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2026Review
- Recent Advances in the Therapeutic Prospective of Heterocyclic Derivatives as COX-2 Inhibitors (2019-Present).Mini reviews in medicinal chemistry · 2026Review
- Zinc complex with quinoline-based thiazolyl-hydrazone targeting DNA replication in cancer cells.Scientific reports · 2025Article
- An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors.Molecular diversity · 2025Review
- Novel di-aryl chalcone derived pyrazole linked to methane sulfonyl pharmacophore as potent selective COX-2 inhibitors; design, synthesis, molecular modeling,Future medicinal chemistry · 2025Article
- Recent advances in targeting COX-2 for cancer therapy: a review.RSC medicinal chemistry · 2025Review
- Discovery and optimization of 4-(imidazo[1,2-a]pyrimidin-3-yl)thiazol-2-amine derivatives as novel phosphodiesterase 4 inhibitors.Molecular diversity · 2025Article
- Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors.Molecular diversity · 2025Article
- Evaluating the Real-World Use of Topical Diclofenac Sodium Gel 1% Using US Longitudinal Electronic Health Records Database: A study supporting OTC switch.Pain and therapy · 2025Article
- Discovery of novel 4-trifluoromethyl-2-anilinoquinoline derivatives as potential anti-cancer agents targeting SGK1.Molecular diversity · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two new series of pyrazolyl-thiazolidinone/thiazole derivatives
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.